Matches in Wikidata for { <http://www.wikidata.org/entity/Q66065474> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- Q66065474 description "clinical trial" @default.
- Q66065474 description "ensayu clínicu" @default.
- Q66065474 description "klinisch onderzoek" @default.
- Q66065474 description "клінічне випробування" @default.
- Q66065474 description "կլինիկական փորձարկում" @default.
- Q66065474 name "Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer" @default.
- Q66065474 name "Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer" @default.
- Q66065474 type Item @default.
- Q66065474 label "Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer" @default.
- Q66065474 label "Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer" @default.
- Q66065474 prefLabel "Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer" @default.
- Q66065474 prefLabel "Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer" @default.
- Q66065474 P1132 Q66065474-D0D89A36-3DAF-4110-81FC-C40CED057D65 @default.
- Q66065474 P1476 Q66065474-0699F831-9BD3-4DEB-8A52-86E995FF8DC5 @default.
- Q66065474 P2899 Q66065474-51EE0334-9AD6-401F-965E-5134ECB61401 @default.
- Q66065474 P3098 Q66065474-2D1BD5BB-BF53-4B61-89D0-2DA671C645E6 @default.
- Q66065474 P31 Q66065474-F514A844-539E-4EFE-B475-022E39FD2164 @default.
- Q66065474 P580 Q66065474-3ABF1D77-7B38-46C0-8BFE-4FF9E6AC144D @default.
- Q66065474 P582 Q66065474-54CE9B29-41AC-46DF-B43A-B450F2366731 @default.
- Q66065474 P6099 Q66065474-408DF9E2-2B39-4ED2-8157-F9EF95251C60 @default.
- Q66065474 P6153 Q66065474-2D8CC8F5-E666-4834-A604-D94F7AE6B5DD @default.
- Q66065474 P6153 Q66065474-331B316F-6E10-47EB-8F2E-929C46CCE4DA @default.
- Q66065474 P6153 Q66065474-42686AD3-3140-42E7-989D-8C178FD557CB @default.
- Q66065474 P6153 Q66065474-621D9E43-CCB0-4C22-9F1E-3E135BA9C603 @default.
- Q66065474 P6153 Q66065474-682E413B-E85E-479B-B947-8BB7CEF426FF @default.
- Q66065474 P6153 Q66065474-753953B6-35BF-45AD-A5E7-6AED11860D6E @default.
- Q66065474 P6153 Q66065474-9D4E64D3-0B21-4121-966F-279D3995438C @default.
- Q66065474 P6153 Q66065474-A6D02757-30B4-4866-AA75-2D08D32FD3F9 @default.
- Q66065474 P6153 Q66065474-BDBFEE07-4B51-4BC7-9045-6290E0E9C8BC @default.
- Q66065474 P6153 Q66065474-D731AF36-2DE3-40AE-B508-3FC5EC118640 @default.
- Q66065474 P8363 Q66065474-90AB6A78-A957-4E9B-98D6-C949311EFDC6 @default.
- Q66065474 P1132 "+200" @default.
- Q66065474 P1476 "A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer" @default.
- Q66065474 P2899 "+18" @default.
- Q66065474 P3098 "NCT03969121" @default.
- Q66065474 P31 Q30612 @default.
- Q66065474 P580 "2019-06-16T00:00:00Z" @default.
- Q66065474 P582 "2020-10-30T00:00:00Z" @default.
- Q66065474 P6099 Q42824827 @default.
- Q66065474 P6153 Q11070014 @default.
- Q66065474 P6153 Q11525644 @default.
- Q66065474 P6153 Q11589960 @default.
- Q66065474 P6153 Q1418766 @default.
- Q66065474 P6153 Q30264604 @default.
- Q66065474 P6153 Q39913 @default.
- Q66065474 P6153 Q491082 @default.
- Q66065474 P6153 Q598841 @default.
- Q66065474 P6153 Q700801 @default.
- Q66065474 P6153 Q7451677 @default.
- Q66065474 P8363 Q78089383 @default.